EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access · CC BY 4.0

Hedgehog Inhibitors Beyond Clinical Complete Response in Basal Cell Carcinoma: Should I Stop or Should I Go?

Salvatore Alfieri iD, Rebecca Romanò, Sara Marceglia, Vincenzo De Giorgi, Ketty Peris, Pietro Sollena, Alfredo Piccerillo, Ruggero Moro, Giulio Gualdi, Paolo Antonio Ascierto, Marco Palla, Miriam Paone und 10 weitere

The Oncologist · 03.05.2024 · 29 (5) · e699-e707

DOI: 10.1093/oncolo/oyad319 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift The Oncologist, online erschienen am 21.12.2023. Verfasst von Salvatore Alfieri und 21 weiteren Autor:innen. Beteiligte Einrichtung: Head and Neck Medical Oncology Department, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy. Hauptthemen laut MEDLINE: Basal Cell Carcinoma, Anilides, Pyridines, Hedgehog Proteins. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

In advanced basal cell carcinoma (BCC), the issue of whether Hedgehog inhibitors (HHIs) should be stopped or not after clinical complete response (cCR) achievement remains an unmet clinical need. Materials and Methods We conducted a retrospective, multicenter study across 7 Italian dermato-oncology units including patients with BCC who continued vismodegib after cCR between 2012 and 2019. We assessed the relationship between the duration of vismodegib intake (days to cCR [DTCR], days to stop after cCR [DTS], total treatment days [TTD]), and disease-free survival (DFS). Reasons to stop vismodegib were (R1) toxicity and (R2) disease recurrence. The relationship between DTCR, DTS, TTD, and DFS in the whole population and in R1 subgroup was assessed by Pearson’s correlation coefficient (P < .05) and Bayesian statistics (BF10).

Results

Sixty-eight BCC patients with a median (m) age of 75.5 years (39-100) were included. Most patients were male (N = 43, 63%), without Gorlin syndrome (N = 56, 82%) and with head and neck area as primary site (N = 51, 75%). After cCR, out of 68 patients, 90% (N = 61/68) discontinued vismodegib: 82% (N = 50/61) due to toxicity (R1), and 18% (N = 11/61) due to recurrence (R2). Conversely, 10% (N = 7/68) continued vismodegib until last follow-up. In the whole population (N = 68), cCR was achieved with a mDTCR of 180.50 days. DFS showed a significant correlation with DTS (P < .01, BF10 = 39.2) and TTD (P < .01, BF10 = 35566), while it was not correlated to DTCR (BF10 < 0.1). The analysis of R1 subgroup (N = 50) confirmed these results. DFS correlated with DTS in all recurrent patients (N = 38, r = 0.44, P < .01) and in the recurrent patients who stopped vismodegib for toxicity (N = 26, r = 0.665, P < .01). DFS was longer when vismodegib was maintained for >2 months after cCR (mDFS > 2 months, N = 54 vs. ≤ 2 months, N = 14: 470 vs. 175 d, P < .01).

Conclusions

Our retrospective results suggest that HHIs should be continued after cCR to improve DFS in BCC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Basal Cell CarcinomaAnilidesPyridinesHedgehog ProteinsSkin NeoplasmsHumansMaleFemaleAgedRetrospective StudiesMiddle AgedAged, 80 and overAdultNeoplasm Recurrence, Local

Stichwörter der Autor:innen

basal cell carcinomabeyond complete responsehedgehog inhibitorsmaintenance therapysonidegibvismodegib

Substanzen

HhAntag691AnilidesPyridinesHedgehog Proteins

Autor:innen und Institutionen

  • Head and Neck Medical Oncology Department, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy.
  • Department of Engineering and Architecture, University of Trieste, Trieste, Italy.
  • Section of Dermatology, Department of Health Sciences, University of Florence, Firenze, Italy.
  • UOC di Dermatologia, Dipartimento di Scienze Mediche e Chirurgiche Addominali ed Endocrino Metaboliche, Fondazione Policlinico Universitario A Gemelli - IRCCS, Roma, Italy.
  • Dermatologia, Dipartimento di Medicina e Chirurgia Traslazionale, Università Cattolica del Sacro Cuore, Roma, Italy.
  • Escuela de Doctorado, Universidad Católica de Valencia San Vicente Martir, Valencia, Spain.

ORCID-Profile: Salvatore Alfieri

Zitieren

APA

Alfieri, S., Romanò, R., Marceglia, S., De Giorgi, V., Peris, K., Sollena, P., Piccerillo, A., Moro, R., Gualdi, G., Ascierto, P. A., Palla, M., Paone, M., Eibenschutz, L., Spagnolo, F., Queirolo, P., Filippini, D. M., Cavalieri, S., Resteghini, C., Bergamini, C., …, & Bossi, P. (2024). Hedgehog Inhibitors Beyond Clinical Complete Response in Basal Cell Carcinoma: Should I Stop or Should I Go?. The Oncologist, 29(5), e699-e707. https://doi.org/10.1093/oncolo/oyad319

Vancouver

Alfieri S, Romanò R, Marceglia S, De Giorgi V, Peris K, Sollena P, et al. Hedgehog Inhibitors Beyond Clinical Complete Response in Basal Cell Carcinoma: Should I Stop or Should I Go?. The Oncologist. 2024;29(5):e699-e707. doi:10.1093/oncolo/oyad319

BibTeX
@article{Alfieri2024,
  author = {Alfieri, Salvatore and Romanò, Rebecca and Marceglia, Sara and De Giorgi, Vincenzo and Peris, Ketty and Sollena, Pietro and Piccerillo, Alfredo and Moro, Ruggero and Gualdi, Giulio and Ascierto, Paolo Antonio and Palla, Marco and Paone, Miriam and Eibenschutz, Laura and Spagnolo, Francesco and Queirolo, Paola and Filippini, Daria Maria and Cavalieri, Stefano and Resteghini, Carlo and Bergamini, Cristiana and Manocchio, Antonello and Licitra, Lisa and Bossi, Paolo},
  title = {Hedgehog Inhibitors Beyond Clinical Complete Response in Basal Cell Carcinoma: Should I Stop or Should I Go?},
  journal = {The Oncologist},
  year = {2024},
  volume = {29},
  number = {5},
  pages = {e699--e707},
  doi = {10.1093/oncolo/oyad319}
}
Kostenlos starten →